1. Home
  2. CPZ vs NERV Comparison

CPZ vs NERV Comparison

Compare CPZ & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Calamos Long/Short Equity & Dynamic Income Trust

CPZ

Calamos Long/Short Equity & Dynamic Income Trust

HOLD

Current Price

$14.32

Market Cap

297.4M

Sector

Finance

ML Signal

HOLD

Logo Minerva Neurosciences Inc

NERV

Minerva Neurosciences Inc

HOLD

Current Price

$7.85

Market Cap

269.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CPZ
NERV
Founded
N/A
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
297.4M
269.6M
IPO Year
2017
2014

Fundamental Metrics

Financial Performance
Metric
CPZ
NERV
Price
$14.32
$7.85
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$7.00
AVG Volume (30 Days)
72.8K
160.1K
Earning Date
01-01-0001
07-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$41,175,600.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.38
$1.15
52 Week High
$16.82
$12.46

Technical Indicators

Market Signals
Indicator
CPZ
NERV
Relative Strength Index (RSI) 31.56 67.71
Support Level N/A $5.34
Resistance Level $15.13 $12.46
Average True Range (ATR) 0.21 0.65
MACD -0.05 0.07
Stochastic Oscillator 9.87 79.94

Price Performance

Historical Comparison
CPZ
NERV

About CPZ Calamos Long/Short Equity & Dynamic Income Trust

Calamos L/S Equity & Dynamic Inc Trust is a trust company that seeks to provide current income and risk-managed capital appreciation, with an investment objective to deliver total return through a combination of capital appreciation and current income. The Fund invests in securities across sectors such as Industrials, Healthcare, Financials, Consumer Discretionary, and others, and holds securities with a broad range of maturities, with the average term to maturity typically ranging from two to ten years. Managed assets represent the Fund's total assets, including any assets attributable to leverage that may be outstanding, minus total liabilities other than debt representing financial leverage.

About NERV Minerva Neurosciences Inc

Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Share on Social Networks: